EMBECTA DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Embecta Corp. Investors to Secure Counsel Before Important August 17 Deadline in Securities Class Action - EMBC

Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Embecta Corp. (NASDAQ: EMBC) between November 25, 2025 and May 4, 2026, inclusive (the "Class Period"), of the important August 17, 2026 lead plaintiff deadline.

If you purchased Embecta common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

To join the Embecta class action, go to https://rosenlegal.com/cases/embecta-corp/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 17, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or concealed material adverse facts concerning the true state of Embecta's fiscal results; pertinently, Embecta knew or recklessly disregarded that Embecta's guidance was misleading and unattainable. In fact, Embecta touted Embecta's pen needle business as "incredibly resolute" mere weeks prior to missing expectations and cutting 2026 fiscal guidance.

When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Embecta class action, go to https://rosenlegal.com/cases/embecta-corp/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.